Implantable Insulin Pump in Type II Diabetes

Michael Bergman; Stephen Olczak; Patricia B. Carroll; William M. Rupp; Jose J. Barbosa; Perry J. Blackshear; Hildy B. Mccarthy; Thomas D. Rohde; Fay J. Goldenberg; Thomas G. Rublein; Frank B. Dorman; Henry Buchwald

doi:10.1056/NEJM198212163072513

Implantable Insulin Pump in Type II Diabetes

Michael Bergman, Stephen Olczak, Patricia B. Carroll, William M. Rupp, Jose J. Barbosa, Perry J. Blackshear, Hildy B. Mccarthy, Thomas D. Rohde, Fay J. Goldenberg, Thomas G. Rublein, Frank B. Dorman, Henry Buchwald

Surgery

Research output: Contribution to journal › Letter › peer-review

1 Scopus citations

Abstract

To the Editor: In their article on the use of an implantable pump (July 29 issue),¹ Rupp et al. demonstrated that normal triglyceride values could be further reduced by means of intravenous insulin infusion in nonobese patients with Type II diabetes. Several groups of workers^{2 3 4} have already reported that subcutaneous insulin infusion restores triglyceride concentrations to normal in Type I diabetics. The presumed mechanism for this reduction is the stimulation of lipoprotein lipase activity, which is deficient during insulin deprivation, resulting in the enhanced clearance of triglyceride-rich particles.⁵ The hypertriglyceridemia commonly observed in obese Type II diabetics is related to. . .

Original language	English (US)
Pages (from-to)	1579-1580
Number of pages	2
Journal	New England Journal of Medicine
Volume	307
Issue number	25
DOIs	https://doi.org/10.1056/NEJM198212163072513
State	Published - Dec 16 1982

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access

10.1056/NEJM198212163072513

OpenUrl availability

Full text

Cite this

@article{fb7dc59721a14bd78be140ce65de08b1,

title = "Implantable Insulin Pump in Type II Diabetes",

abstract = "To the Editor: In their article on the use of an implantable pump (July 29 issue),1 Rupp et al. demonstrated that normal triglyceride values could be further reduced by means of intravenous insulin infusion in nonobese patients with Type II diabetes. Several groups of workers2 3 4 have already reported that subcutaneous insulin infusion restores triglyceride concentrations to normal in Type I diabetics. The presumed mechanism for this reduction is the stimulation of lipoprotein lipase activity, which is deficient during insulin deprivation, resulting in the enhanced clearance of triglyceride-rich particles.5 The hypertriglyceridemia commonly observed in obese Type II diabetics is related to. . .",

author = "Michael Bergman and Stephen Olczak and Carroll, {Patricia B.} and Rupp, {William M.} and Barbosa, {Jose J.} and Blackshear, {Perry J.} and Mccarthy, {Hildy B.} and Rohde, {Thomas D.} and Goldenberg, {Fay J.} and Rublein, {Thomas G.} and Dorman, {Frank B.} and Henry Buchwald",

year = "1982",

month = dec,

day = "16",

doi = "10.1056/NEJM198212163072513",

language = "English (US)",

volume = "307",

pages = "1579--1580",

journal = "New England Journal of Medicine",

issn = "0028-4793",

publisher = "Massachussetts Medical Society",

number = "25",

}

TY - JOUR

T1 - Implantable Insulin Pump in Type II Diabetes

AU - Bergman, Michael

AU - Olczak, Stephen

AU - Carroll, Patricia B.

AU - Rupp, William M.

AU - Barbosa, Jose J.

AU - Blackshear, Perry J.

AU - Mccarthy, Hildy B.

AU - Rohde, Thomas D.

AU - Goldenberg, Fay J.

AU - Rublein, Thomas G.

AU - Dorman, Frank B.

AU - Buchwald, Henry

PY - 1982/12/16

Y1 - 1982/12/16

N2 - To the Editor: In their article on the use of an implantable pump (July 29 issue),1 Rupp et al. demonstrated that normal triglyceride values could be further reduced by means of intravenous insulin infusion in nonobese patients with Type II diabetes. Several groups of workers2 3 4 have already reported that subcutaneous insulin infusion restores triglyceride concentrations to normal in Type I diabetics. The presumed mechanism for this reduction is the stimulation of lipoprotein lipase activity, which is deficient during insulin deprivation, resulting in the enhanced clearance of triglyceride-rich particles.5 The hypertriglyceridemia commonly observed in obese Type II diabetics is related to. . .

AB - To the Editor: In their article on the use of an implantable pump (July 29 issue),1 Rupp et al. demonstrated that normal triglyceride values could be further reduced by means of intravenous insulin infusion in nonobese patients with Type II diabetes. Several groups of workers2 3 4 have already reported that subcutaneous insulin infusion restores triglyceride concentrations to normal in Type I diabetics. The presumed mechanism for this reduction is the stimulation of lipoprotein lipase activity, which is deficient during insulin deprivation, resulting in the enhanced clearance of triglyceride-rich particles.5 The hypertriglyceridemia commonly observed in obese Type II diabetics is related to. . .

UR - http://www.scopus.com/inward/record.url?scp=0020485521&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0020485521&partnerID=8YFLogxK

U2 - 10.1056/NEJM198212163072513

DO - 10.1056/NEJM198212163072513

M3 - Letter

C2 - 6755253

AN - SCOPUS:0020485521

SN - 0028-4793

VL - 307

SP - 1579

EP - 1580

JO - New England Journal of Medicine

JF - New England Journal of Medicine

IS - 25

ER -

Implantable Insulin Pump in Type II Diabetes

Abstract

UN SDGs

Access

OpenUrl availability

Other files and links

Fingerprint

Cite this